Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Status:
Suspended
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to determine the maximal tolerated dose (MTD) of
PAC-1 in combination with temozolomide in patients with high grade glioma: glioblastoma
multiforme (GBM) or anaplastic astrocytoma after progression following standard first line
therapy (Component 2), by evaluation of toxicity and tolerability.